Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: A randomized, double-blinded, placebo-controlled trial

• Published in: Journal of the American Academy of Dermatology 2012-10, Vol.67 (4), p.694-699
• Main Authors: Xia, Yang, MD, Cho, Sunghun, MD, Howard, Robin S., MA, Maggio, Kurt L., MD
• Format: Article
• Language: English
• Subjects: Administration, Topical; Adult; Biological and medical sciences; Combined Modality Therapy; Dermatology; Double-Blind Method; Eflornithine - administration & dosage; eflornithine hydrochloride; Emollients - administration & dosage; Enzyme Inhibitors - administration & dosage; Follow-Up Studies; Hair Diseases - drug therapy; hair laser; Hair Removal - methods; Hair Removal - standards; Humans; Laser Therapy; Lasers, Solid-State - therapeutic use; Male; Medical sciences; Military Personnel; Neck; Placebos; pseudofolliculitis barbae; Treatment Outcome; Young Adult
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2011.10.029

Background Pseudofolliculitis barbae (PFB) significantly impacts the military population, especially deployed personnel. Objective This study was designed to determine whether the addition of topical eflornithine to hair laser treatment would improve efficacy in treating PFB. Methods This was a randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining a combination of eflornithine and hair laser versus placebo and hair laser for the treatment of PFB. In all, 27 male patients with clinical PFB were treated with a long-pulsed neodymium:yttrium-aluminum-garnet laser with an energy fluence of 25 to 30 J/cm2 , a pulse duration of 20 to 30 milliseconds, and a 10-mm spot size to the entire bearded neck region. The laser treatment was performed every 4 weeks for a total of 16 weeks. Between laser treatments, patients applied eflornithine and placebo creams twice daily to opposite sides of the bearded neck region. The number of hairs and inflammatory papules were counted bilaterally at each visit. Results The eflornithine side had a statistically significant decrease in the number of hairs and inflammatory papules compared with the placebo side. At 16 weeks, the eflornithine side had a median hair reduction of 99.5% from baseline (range 48.5%-100.0%), whereas the placebo side had an 85.0% median hair reduction from baseline (range 50.5%-94.5%), P less than .001. Limitations Patients were not followed up beyond 16 weeks. Conclusion The addition of topical eflornithine to hair laser treatment decreased hairs and inflammatory papules faster when compared with hair laser therapy alone in the treatment of PFB.